Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-03-21 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于召开2022年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2022 annual performance explanation meeting (业绩说明会) to be held on March 30, 2023. It provides details about the meeting time, location, format (online interaction), participants, and how investors can participate and ask questions. The document does not contain actual financial statements or detailed financial analysis but rather informs investors about the upcoming event where such information will be discussed. This matches the description of an Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, typically involving interactive sessions. The document is not the annual report itself, nor is it a brief announcement or a certification. Therefore, the correct classification is Investor Presentation (IP).
2023-03-21 Chinese
长春百克生物科技股份公司第五届董事会独立董事关于第五届董事会第十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Changchun Baike Biotechnology Co., Ltd. regarding the twelfth meeting of the fifth board of directors. It discusses the prudence and compliance of asset impairment provisions and inventory write-offs for the year 2022. The document is a formal statement of opinion related to board meeting matters, not a full financial report or audit report. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it contains substantive content. This fits best under Board/Management Information (MANG), as it relates to board meeting opinions and governance matters.
2023-02-24 Chinese
长春百克生物科技股份公司第五届监事会第九次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the approval of asset impairment and inventory write-off for the year 2022. It includes details about the meeting date, attendance, and voting results. It references compliance with accounting standards and company policies but does not contain detailed financial statements or comprehensive financial analysis. The document also points to a separate announcement (2023-006) for more details. Given the nature of the content, this is a regulatory announcement related to internal governance and financial decisions but not a full audit report or annual/interim report. It is not a report publication announcement since it contains substantive meeting resolution content. Therefore, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2023-02-24 Chinese
《长春百克生物科技股份公司信息披露暂缓与豁免事务管理制度》
Governance Information Classification · 95% confidence The document is a detailed internal management system for information disclosure delay and exemption for Changchun Baike Biotechnology Co., Ltd. It outlines procedures, responsibilities, and legal references related to delaying or exempting disclosure of certain information. It does not contain financial data, earnings, audit results, or any report of financial performance. It is a governance-related document describing internal rules and compliance procedures for information disclosure management. The document length is 3679 characters, which is relatively short and does not represent a financial report or announcement of a report. Therefore, it fits best under Governance Information (CGR).
2023-02-24 Chinese
长春百克生物科技股份公司关于2022年度计提资产减值准备及存货报废的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the board of directors regarding the company's 2022 asset impairment provisions and inventory write-offs. It details the amounts and reasons for these accounting adjustments, including the impact on the company's 2022 consolidated profit. The document includes opinions from the board, audit committee, independent directors, and supervisory board, confirming the appropriateness and compliance of the provisions with accounting standards. The document is relatively short (2668 characters) and serves as a formal disclosure of specific accounting decisions rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed audit results but rather a specific announcement about impairment and inventory write-offs. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other categories.
2023-02-24 Chinese
长春百克生物科技股份公司2022年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2022年度业绩快报公告" which translates to "2022 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2022, including revenue, profit, and asset figures, but explicitly states that the data is unaudited and preliminary, with final audited data to be found in the company's full 2022 Annual Report. The document is relatively short (1854 characters) and serves as a quick earnings update rather than a full comprehensive report. It also includes a risk warning and notes about the impact of COVID-19 on performance. This type of document corresponds to an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only, not the full detailed annual report (10-K). FY 2022
2023-02-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.